Why Eli Lilly Is a Buy After Earnings. The Stock Got an Upgrade. -- Barrons.com
Eli Lilly Analyst Ratings
Barclays Remains a Buy on Eli Lilly & Co (LLY)
Eli Lilly Price Target Raised to $1000.00/Share From $875.00 by Wells Fargo
Eli Lilly & Co: A Balanced Hold Rating Amid Growth and Competitive Challenges
Redburn Atlantic Adjusts Eli Lilly Price Target to $640 From $600
Jefferies Remains a Buy on Eli Lilly & Co (LLY)
Eli Lilly Analyst Ratings
Eli Lilly & Co (LLY) Buy Rating Affirmed on Strong HFpEF Data and Competitive Edge Over Novo Nordisk (NVO)
Eli Lilly Analyst Ratings
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,041
Eli Lilly & Co Faces European Market Challenges; Analyst Maintains Hold Rating
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Eli Lilly & Co (LLY) Gets a Buy From Barclays
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $885
Eli Lilly and Co Analyst Ratings
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,117